PANAVANCE

Panavance Therapeutics Inc. is a privately-held, clinical-stage pharmaceutical company developing a novel oncology platform focused on improving the outcomes and quality of life for cancer patients. Panavance, a US Delaware company, is located in Berwyn, PA. It was founded in 2021 and is a subsidiary of Swiss privately held Ed. Geistlich Söhne AG für Chemische Industrie... We are focused on giving every patient the best possible chance to live a healthy and cancer-free life. Our clinical-stage drug GP-2250 is bringing new hope to the fight against cancer through truly novel science... Panavance's lead program, misetionamide (also known as GP-2250), is a tumor cell selective and broadly active small molecule with a unique dual mechanism of action of selectively disrupting the energy metabolism of cancer cells leading to cancer cell death as well as impacting nuclear factor-κB ("NFκB") which effects cancer cells' ability for protein synthesis and DNA transcription thereby restricting..

Also known as: Panavance Therapeutics, Panavance Therapeutics Inc.